Hadassah

Hadassah Study Sheds Encouraging Light in Treating Liver Disease

Thursday, Oct 17 2019

The International Journal of Molecular Medicine has published a pre-clinical study led by Prof. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit, that finds the oral drug Namodenoson has induced significant anti-inflammatory, anti-steatotic (retention of lipids), and anti-fibrotic (scarring) effects caused by non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 

The research team identified the mechanism by which the treatment proved effective, explaining that the drug targets the overexpression of the A3 adenosine receptor. Can-Fite BioPharma Ltd, which developed the drug, notes that the A3 adenosine receptor is highly expressed in diseased cells, but not in normal cells, which accounts for the excellent safety profile of Namodenoson.

The comprehensive study tested the effects of Namodenoson on two different NASH mice models and on a cell line of human liver cells that resemble the metabolic phenotype observed in NASH patients. 

Prof. Safadi is now conducting a Phase II study with Namodenoson in NASH and NAFLD patients who show evidence of active inflammation. The focus is on measuring the drug’s anti-inflammatory effect and its success in reducing fat in the liver.

Prof. Safadi reports that “the growing amount of data showing Namodenoson’s liver protective properties is highly encouraging as the Phase II clinical study in NASH nears completion. Namodenoson can potentially serve a clear and unmet need, since the U.S. Food and Drug Administration has yet to approve a drug specifically to treat NAFLD and NASH. We are pleased to work with Can-Fite on this pre-clinical study and hope to show similar data in human patients.”

Learn more about the Hadassah Medical Organization.

Related Stories

alt_text

Wednesday, Nov 13 2019

After Years of Unidentified Pain, Teenager Finds Relief at Hadassah

A very active, athletic 17-year-old girl arrived at Hadassah Hospital Ein Kerem complaining of pain in her stomach. She had no idea there was a massive growth in her abdomen that weighed more than six pounds.

READ MORE ›
alt_text

Tuesday, Nov 12 2019

Hadassah Experts Offer Information and Advice on Infant Sleep Issues

Hadassah Experts Offer Information and Advice on Infant Sleep Issues 

READ MORE ›
alt_text

Tuesday, Nov 5 2019

First-Ever Magen David Adom Dispatch Center Dedicated at Hadassah

The first-ever Magen David Adom (MDA) Emergency Ambulance Dispatch Center was dedicated at Hadassah Hospital Ein Kerem on October 31.

READ MORE ›
alt_text

Thursday, Oct 31 2019

Hadassah/Oxford Study of Bone Fragility Among Diabetics Receives Grant

Prof. Rivka Dresner Pollak, head of the Hadassah Medical Organization’s Department of Endocrinology and Metabolism, together with University of Oxford colleague Prof. Lynne Cox, has received funding...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More